Sign up
Pharma Capital

Akari Therapeutics expects readouts from two key Phase II studies by year-end

Clive Richardson, chief executive of Akari Therapeutics PLC (NASDAQ:AKTX), introduces the business to Proactive London and outlines some of the work they're doing in the area of acute and chronic inflammation.

Discussing their protein Nomacopan, he says it's currently being clinically evaluated in four indications including a severe blistering skin disease and a sight threatening surface of the eye condition.


View full AKTX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.